T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Niels J.M. Verstegen, Ruth R. Hagen, Christine Kreher, Lisan H. Kuijper, Jet van den Dijssel, Thomas Ashhurst, Laura Y.L. Kummer, Virginia Palomares Cabeza, Maurice Steenhuis, Mariël C. Duurland, Rivka de Jongh, C. Ellen van der Schoot, Veronique A.L. Konijn, Erik Mul, Katherine Kedzierska, Koos P.J. van Dam, Eileen W. Stalman, Laura Boekel, Gertjan Wolbink, Sander W. TasJoep Killestein, Theo Rispens, Luuk Wieske, Taco W. Kuijpers, Filip Eftimov, Zoé L.E. van Kempen, S. Marieke van Ham, Anja ten Brinke*, Carolien E. van de Sandt*,

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination'. Together they form a unique fingerprint.

Immunology and Microbiology